Alkermes Plc
Change company Symbol lookup
Select an option...
ALKS Alkermes Plc
CPTNW Cepton Equity Warrant Exp 10th Feb 2027 *W EXP 02/10/2027
APPF Appfolio Inc
FMN Federated Hermes Premier Municipal Inc
USCTU TKB Critical Technologies 1
SIEGY Siemens AG
FDBC Fidelity D&D Bancorp Inc
$BUKCHET Bloomberg Coffee Subindex Euro
BMY Bristol-Myers Squibb Co
MLGO MicroAlgo Inc
Go

Health Care : Biotechnology | Small Cap Growth
Based in Ireland
Company profile

Alkermes Public Limited Company is an integrated biopharmaceutical company. It is engaged in researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Its portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Its products include ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder. VIVITROL is a non-narcotic, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.

Closing Price
$27.10
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Below Average)
Volume:
978,528

10-day average volume:
1,145,105
978,528

Booking profit more than doubles, beating expectations; stock rises

8:16 am ET November 3, 2022 (MarketWatch)
Print

By Levi Sumagaysay

Booking Holdings Inc. stock rose sharply in extended trading Wednesday as the company's third-quarter profit more than doubled and its results beat Wall Street expectations across the board.

Booking (BKNG) shares rose more than 5% after hours, after falling nearly 6% in the regular session to close at $1,778.18. Shares of Booking, Expedia Group Inc. (EXPE) and others in the travel industry sank in regular trading Wednesday after Airbnb Inc. (ABNB)reported its financial results Tuesday and issued a fourth-quarter outlook that worried investors; Booking shares have dropped in four of the past six sessions.

Booking, whose brands include Priceline, Kayak and Booking.com, reported that gross travel bookings for the third quarter were $32.1 billion, up 36% from the year-ago period. That exceeded analysts' expectation of $30.48 billion in gross bookings. Room nights booked were 240 million, beating analysts' expectation of 232.8 million.

"I am encouraged by the strong results we are reporting today, including the highest amount of quarterly revenue and adjusted Ebitda ever for our company," Chief Executive Glenn Fogel said in a statement.

On the company's earnings call with analysts, Fogel said he saw improvements in all major regions in August and September compared with July, and that in September, room nights in Asia surpassed 2019 levels for the first time.

"Despite macroeconomic concerns and uncertainty, we believe the sustained level of demand demonstrates consumers' desire to travel," Fogel said.

Booking offers listings of both hotels and alternative accommodations, and its CEO said that the company has made progress on alternative accommodations. Room nights for alternative accommodations booked on Booking.com rose 11% compared with the same period in 2019, and represented 30% of total nights booked, Fogel said.

The company reported that third-quarter net income more than doubled to $1.67 billion, or $41.98 a share, compared with $769 million, or $18.60 a share, in the year-ago period. Adjusted for losses from investments and unrecognized tax benefits, earnings were $53.03 a share. Revenue rose to $6 billion from $4.67 billion in the year-ago quarter.

Adjusted earnings before interest, taxes, depreciation and amortization were $2.7 billion, up 26% year over year.

Analysts surveyed by FactSet had forecast adjusted earnings of $49.52 a share on revenue of $5.92 billion.

Chief Financial Officer David Goulden said on the call that he expects fourth-quarter sales to rise year over year, and adjusted Ebitda to be above $1.4 billion. Analysts are forecasting fourth-quarter earnings of $22.79 a share on revenue of $3.9 billion, and Ebitda of $1.22 billion.

Shares of Booking have declined almost 26% so far this year, and are on pace for their worst year since 2008, when they sank almost 36%. By comparison, the S&P 500 index has fallen about 21% year to date.

-Levi Sumagaysay

	

(END) Dow Jones Newswires

November 03, 2022 08:16 ET (12:16 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.